Re-reading the 1984 Biomatrix Inc US4636524A by Endre A. Balazs and Adolf Leshchiner — the 'Cross-linked gels of hyaluronic acid' patent that became the origin of modern aesthetic-medicine fillers, joint injections, and sustained-release formulations

About excavation memos: "Excavation memos" in this series record candidate summaries at the stage where the primary URL has been confirmed. This memo retrieves the title, inventors, assignees, dates, and Claim 1 from Google Patents, but the full specification (chemical-reaction conditions for specific crosslinking agents, detailed relationships to Restylane / Juvederm derivative patents, the Biomatrix → Genzyme → Sanofi transfer history) is unread. Only confirmed facts are stated; speculation is marked as such.

This memo is an archive of past documents. Modern medical decisions about aesthetic-medicine fillers, joint injections, etc. must be based on up-to-date sources and professional advice; readers are responsible for their own choices.

Why excavate this

Hyaluronic acid (HA) is now widely used in (a) injectable fillers in aesthetic dermatology (Restylane, Juvederm, Belotero, Teosyal), (b) intra-articular injection for osteoarthritis (Synvisc, Hyalgan, Suplasyn), (c) viscoelastic devices for cataract surgery (Healon, Provisc), (d) cosmetics moisturizers, and (e) some sustained-release drug-delivery formulations. The material foundation of these injectable / implantable HA formulations is not native HA injected as is, but crosslinked HA gels with stabilized molecular networks. This patent, US4636524A, is the starting patent that cordons off, in Claim 1, a sustained-release system that disperses a substance in a crosslinked HA gel.

As the molecular-cage slot of Day 19's three-piece set 'Cage Patents — confining electrons, charge, and molecules,' this memo joins ep70 flash memory (electron cage = floating gate) and ep71 CCD (charge cage = potential well). Claim 1 verbatim writes "molecular cage formed of a cross-linked gel of hyaluronic acid... having dispersed therein a substance," so the patent expresses the very concept of "confining a substance in a molecular cage" in the language of patent claims. This is what makes it perfectly aligned with the other two Day 19 articles.

Patent basic information

Patent number: US4636524A
Title: Cross-linked gels of hyaluronic acid and products containing such gels
Inventors: Endre A. Balazs / Adolf Leshchiner (two co-inventors)
Original Assignee: Biomatrix Inc (Ridgefield, NJ, the bio-materials company Balazs co-founded in 1981)
Current Assignee: Sanofi Biosurgery Inc (Biomatrix was acquired by Genzyme in 2000; Genzyme by Sanofi in 2011)
Priority Date: 1984-12-06
Filing Date (US): 1985-03-08
Grant Date: 1987-01-13
Status: Expired - Lifetime

DB match: two DB corrections occurred (the third / fourth corrections this session, alongside ep70 flash):

(1) DB "Endre Balazs (Columbia University)" solo assumption → reality "Endre A. Balazs + Adolf Leshchiner two co-inventors." Leshchiner is a Biomatrix Inc chemist, presumed (primary source unconfirmed) to have implemented the crosslinking process (using divinyl sulfone and similar reagents). The same pattern as Day 17 ep64 Goodenough/Mizushima, Day 18 ep68 Nakamura/Mukai/Iwasa, and Day 19 ep70 Masuoka/Iizuka — the gap between "narrativized lone inventor" and "patent inventor field" continues.

(2) DB "Columbia University / Matrix Biology Institute assignee" → reality "Original Assignee Biomatrix Inc / Current Assignee Sanofi Biosurgery Inc." Balazs's career path was: Professor of Ophthalmology at Columbia University Medical School (1968-1975); Director of the Matrix Biology Institute, Ridgefield, NJ (1975-1981); co-founder of Biomatrix Inc in 1981. At filing (1984), his affiliation was Biomatrix Inc. The DB's "Columbia University" entry confuses Balazs's earlier and current affiliations.

Day 8-19 cumulative DB-error correction sequence updates from 27 to 28 (three corrections concurrent within Day 19 — among the highest, comparable to Day 15's three corrections).

Claim 1 (verbatim from primary source)

The Claim 1 retrieved from Google Patents:

A delivery system for a substance having biological or pharmacological activity, said system comprising a molecular cage formed of a cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer co-polymerizable therewith and having dispersed therein a substance having biological or pharmacological activity and which is capable of being diffused therefrom in a controlled manner.

Four core points of Claim 1:

The phrase "molecular cage" is written directly into the claim: this is the verbatim expression of the molecular cage in Day 19's Cage Patents axis. Whereas the electron / charge cages elsewhere are read metaphorically as "cages" from physically barrier-bounded structures, this patent uses "molecular cage" directly in the patent-claim language, giving it a unique strength among the three.
Crosslinked HA gel, or mixed crosslinked gel of HA and other hydrophilic polymers: native HA is a single polysaccharide of millions of daltons, but injected directly it is degraded by hyaluronidase in the body within 1-2 days. Crosslinking stabilizes the molecular network, extending the degradation half-life to weeks or months — the commercial core for filler formulations.
Disperses a biologically or pharmacologically active substance: Claim 1 does not restrict the type of drug, covering anti-inflammatories, growth factors, proteins, small-molecule drugs, dyes, and more. This is what makes the patent's scope wide.
Controlled diffusion release ("controlled manner"): the claim includes the function of a sustained-release (sustained release) system. Release rates can be tuned by varying crosslink density, crosslinker type, and gel particle size.

Note: the patent does not specify "aesthetic filler" as a direct use. It covers a broad abstract — "a substance having biological or pharmacological activity" — and subsequent aesthetic uses such as Restylane / Juvederm are read as applications within Claim 1's scope (strict legal judgment depends on derivative patents and is unconfirmed in this memo).

Forty years from 1984 to 2026

1934: Karl Meyer (Columbia University) first isolates HA from bovine vitreous body
1968-1975: Endre Balazs serves as Professor of Ophthalmology at Columbia University Medical School; HA research and Healon (ophthalmic viscoelastic) development
1975-1981: Balazs serves as director of the Matrix Biology Institute (NJ)
1979: Healon is approved as an ophthalmic HA (US, Sweden)
1981: Balazs co-founds Biomatrix Inc (Ridgefield, NJ)
1984-12-06: this patent's Priority Date (crosslinked HA gel sustained-release system)
1985-03-08: US filing
1987-01-13: this patent granted
1996: Restylane (Q-Med, Sweden) approved in EU — the world's first crosslinked HA filler
2003: Restylane approved by FDA (US)
2006: Juvederm (Allergan) approved by FDA
2000: Biomatrix Inc acquired by Genzyme
2011: Genzyme acquired by Sanofi
2024-2026: the worldwide crosslinked-HA filler market is in the order of $5+ billion; four-company competition among Allergan / Galderma / Merz / Q-Med, with later entrants Korea LG Chemical and China's Bloomage Biotech

Modern correspondence hypothesis

US4636524A (1984 filing / 1987 grant)	Modern correspondence (2026)	Evaluation
Crosslinked-hyaluronic-acid molecular cage	Restylane, Juvederm, Belotero, Teosyal — crosslinked HA fillers	Same (within Claim 1's scope; the freely-implementable environment after expiry expanded the derivative product range)
Controlled diffusion release	Sustained-release drug delivery (some intra-articular injections, local anti-cancer administration)	Similar (the sustained-release concept is shared; modern systems control crosslink density and particle size more precisely)
1984 Biomatrix Inc single company	2026 Allergan / Galderma / Merz / Q-Med / LG Chemical / Bloomage — six-company structure	Analogy (market structure changed; the freely-implementable environment after this patent expired allowed multi-company entry)
HA + hydrophilic-polymer mixed crosslinking	Some HA-lysine / HA-PEG derivative products	Similar (mixed crosslinking is covered by Claim 1; specific combinations are individually protected by derivative patents)

Center of gravity: 1 row of "Same" (Restylane / Juvederm crosslinked-HA fillers). Even 30 years after expiry, the industry as a whole continues to follow the invention concept of "make a molecular cage from crosslinked HA and confine a drug" claimed in this patent.

To be precise (concise three items)

Confirmed facts:

US4636524A, title "Cross-linked gels of hyaluronic acid and products containing such gels," inventors Endre A. Balazs + Adolf Leshchiner two co-inventors, Original Assignee Biomatrix Inc, Current Assignee Sanofi Biosurgery Inc, Priority 1984-12-06, Filing 1985-03-08, Grant 1987-01-13, retrieved via WebFetch from Google Patents
Full text of Claim 1 retrieved. "molecular cage formed of a cross-linked gel of hyaluronic acid" verbatim confirmed.

Author's interpretation:

"Molecular-cage slot of the Cage Patents axis" is an editorial decision in this session. That said, the fact that Claim 1 directly uses the phrase "molecular cage" is itself a fact.
Positioning this as "the ancestor of Restylane / Juvederm" is a lineage placement; the patent rights of derivative formulations from each company are unconfirmed in this memo. Strict legal accuracy requires separate verification.

Unconfirmed:

Full specification text. Which crosslinking agents (divinyl sulfone / formaldehyde / 1,4-butanediol diglycidyl ether) are claimed and which appear as embodiments are unconfirmed.
Legal details of Claim-scope overlap and design-around with Restylane (Q-Med 1996 EU approval) and Juvederm (Allergan 2006 FDA approval) derivative patents
Detailed transfer history of Biomatrix Inc → Genzyme (2000 acquisition) → Sanofi (2011 acquisition)
Adolf Leshchiner's career details (his role at Biomatrix; subsequent activities). The industry literature usually narrates Balazs solo, and individual information on Leshchiner is sparse.
Quantitative relationship between crosslink density / particle size and release half-life as observed in actual aesthetic-medicine clinical practice (industry secondary sources)

References

US Patent US4636524A (Google Patents): https://patents.google.com/patent/US4636524A/en
Endre Balazs Matrix Biology Institute (Balazs's research institution before co-founding Biomatrix): https://matrixbiologyinstitute.org/

Day 19 three-piece set 'Cage Patents'

Note #4: 1980 Masuoka + Iizuka flash memory US4531203A — electrons confined in a floating-gate cage
Memo #6: 1973 Bell Labs Boyle/Smith CCD US3792322A — charge confined in a potential-minima cage
Cosmetic Memo #2 (this article): 1985 Balazs/Leshchiner crosslinked hyaluronic-acid gel US4636524A — drug confined in a molecular cage

The three articles share an editorial axis of patents whose Claim 1 verbatim contains a "confinement structure" — a first attempt in the AI-archaeology series. They span electrons (semiconductor memory) / charge (light detection) / molecules (biomaterials), but share the invention core "physically confining matter for storage / readout / sustained release." This article is special because Claim 1 directly uses the phrase "molecular cage": the other two (electrons, charge) are read metaphorically as cages, while this patent claims the cage in the language of patent claims itself. It forms the strongest basis for the Day 19 axis.